Development of Self-regulation by Dialectial Behavioural Therapy in Adults With Autism
Launched by RADBOUD UNIVERSITY MEDICAL CENTER · Aug 15, 2022
Trial Information
Current as of July 01, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Individuals with autism spectrum disorder (ASD) are at risk to develop more pervasive emotion-dysregulation and in conjunction with that they also show more maladaptive coping compared to non-autistic people. Sensory differences and impaired interoceptive body-awareness may influence emotion-dysregulation. Maladaptive coping is reflected by a variety of harmful behaviours, particularly strong social avoidance, rumination, obsessive-compulsive symptoms, disordered eating, substance abuse, agitation, non-suicidal-self-injury (NSSI), and suicidal ideation and behaviour. For a part of these ind...
Gender
ALL
Eligibility criteria
- The inclusion criteria to enroll in the study are the same as the inclusion criteria for integrative DBT. Inclusion Criteria:
- • Age ≥ 18 years old.
- • A clinical diagnosis of ASD as diagnosed by a qualified health care professional (in Dutch: BIG registration).
- • Non-responding to TAU (treatment as usual) for at least a year.
- • IQ ≥ 85, based upon previous levels of education or previous IQ test, when available.
- • Consent from the participant to record the DBT sessions on video or audio for supervision and assessing therapy integrity.
- • Proficient in the Dutch language.
- • Motivation to address problems through integrative DBT.
- • Ability to work on treatment goals in collaboration with multiple therapists and counselors and to function in a group of maximal 8 adults with ASD.
- Exclusion Criteria:
- • - Severe, current psychotic and manic symptoms, severe substance abuse disorder and eating disorder, requiring other specialized treatment first.
About Radboud University Medical Center
Radboud University Medical Center is a leading academic medical institution located in Nijmegen, the Netherlands, dedicated to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, Radboud UMC leverages its multidisciplinary expertise to conduct high-quality research that aims to improve patient outcomes and enhance medical knowledge. The center is committed to ethical standards and regulatory compliance, fostering collaboration among researchers, healthcare professionals, and patients to translate scientific discoveries into effective clinical applications. With a focus on personalized medicine and cutting-edge technologies, Radboud University Medical Center plays a pivotal role in shaping the future of healthcare through its rigorous clinical trial initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Deventer, Gelderland, Netherlands
Patients applied
Trial Officials
Ella Lobregt-van Buuren, MSc
Principal Investigator
Dimence mental health institute
Nanda Lambregts-Rommelse, PhD
Study Chair
Radboud University Medical Center
Wouter Staal, PhD
Study Chair
Radboud University Medical Center
Lisette Verhoeven, PhD
Study Chair
Dr. Leo Kannerhuis
Peter Goossens, PhD
Study Chair
Dimence mental health institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials